BerGenBio is an oncology biotech company that develops medicines to treat cancer. The Company develops immuno-oncology drugs, inhibitors, and therapeutics. It also develops clinical trial programmes which focuse on treatment of non-small lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as melanoma and triple negative breast cancer.
Market capitalization (10-Nov-2021)
Closing stock price (10-Nov-2021)
When was BerGenBio founded?
BerGenBio was founded in 2008.
Who are BerGenBio key executives?
BerGenBio's key executives are Stener Kvinnsland, Sally Bennett and Nigel McCracken.
How many employees does BerGenBio have?
BerGenBio has 46 employees.
Who are BerGenBio competitors?
Competitors of BerGenBio include Luye Pharma, Dragonfly and BrightPath Biotherapeutics.
Where is BerGenBio headquarters?
BerGenBio headquarters is located at BBB 91 Jonas Lies vei, Bergen.
Where are BerGenBio offices?
BerGenBio has offices in Bergen and Oxford.
How many offices does BerGenBio have?
BerGenBio has 2 offices.
Receive alerts for 300+ data fields across thousands of companies